{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:47:32Z","timestamp":1781891252549,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21 NS120223"],"award-info":[{"award-number":["R21 NS120223"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017618","name":"Division of Diabetes, Endocrinology, and Metabolic Diseases","doi-asserted-by":"publisher","award":["P30DK092926"],"award-info":[{"award-number":["P30DK092926"]}],"id":[{"id":"10.13039\/100017618","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Implementation of guideline-recommended strategies to prevent acute ischemic stroke (AIS) in type 2 diabetes (T2D) remains suboptimal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We evaluated and compared the health impact and cost-effectiveness of improved implementation of guideline-recommended strategies for AIS prevention in patients with T2D in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We compared scenarios with enhanced implementation of these prevention strategies to the status-quo using a microsimulation model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>National Health and Nutrition Examination Survey (NHANES) 2015\u20132018 participants\u2009\u2265\u200945\u00a0years of age with T2D and no stroke history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main measures<\/jats:title>\n                    <jats:p>We evaluated stroke-related events, costs, stroke-related quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios, and net health benefit (NHB) from a health system perspective over a 10-year time horizon. A discount rate of 3% per year was applied to costs and QALYs. Costs were expressed in 2022 U.S. dollars.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>Full implementation of guideline-recommended blood pressure (BP), statin, and aspirin therapies, and smoking cessation would each be cost-saving or highly cost-effective (&lt;\u2009$50,000 per QALY-gained). Over 10\u00a0years, full implementation of all four of the strategies would prevent 151,000 stroke events, 61,900 deaths from stroke, save $13.4 billion, and produce a nationwide increase of 1,552,000 QALYs (NHB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Recent attention has focused on the treatment of AIS. We demonstrate that substantial opportunities exist to improve the primary prevention of AIS in Americans with T2D. Providers and payers should prioritize adherence to guidelines for BP, statin and aspirin therapy, and smoking cessation for stroke prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-025-10067-x","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:57:45Z","timestamp":1765213065000},"page":"1928-1936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness of Primary Prevention of Stroke in Type 2 Diabetes in the United States: A Microsimulation Analysis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-189X","authenticated-orcid":false,"given":"Wen","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaqing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihchen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis B.","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda D.","family":"Lisabeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"10067_CR1","doi-asserted-by":"crossref","unstructured":"Fox CS, Golden SH, Anderson C, et al; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research; American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2015;38:1777\u20131803.","DOI":"10.2337\/dci15-0012"},{"key":"10067_CR2","doi-asserted-by":"publisher","unstructured":"Abilleira S, P\u00e9rez de la Ossa N, Jim\u00e9nez X, et al. Transfer to the local stroke center versus direct transfer to endovascular center of acute stroke patients with suspected large vessel occlusion in the Catalan Territory (RACECAT): Study protocol of a cluster randomized within a cohort trial. Int J Stroke. 2019;14:734\u2013744. https:\/\/doi.org\/10.1177\/1747493019852176","DOI":"10.1177\/1747493019852176"},{"key":"10067_CR3","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1161\/STROKEAHA.119.027843","volume":"51","author":"H Zhao","year":"2020","unstructured":"Zhao H, Coote S, Easton D, et al. Melbourne mobile stroke unit and reperfusion therapy: greater clinical impact of thrombectomy than thrombolysis. Stroke. 2020;51:922\u2013930. https:\/\/doi.org\/10.1161\/STROKEAHA.119.027843","journal-title":"Stroke"},{"key":"10067_CR4","doi-asserted-by":"publisher","first-page":"e527","DOI":"10.1161\/STROKEAHA.121.034222","volume":"52","author":"JR Morey","year":"2021","unstructured":"Morey JR, Zhang X, Marayati NF, et al. Mobile interventional stroke teams improve outcomes in the early time window for large vessel occlusion stroke. Stroke. 2021;52:e527\u2013e530. https:\/\/doi.org\/10.1161\/STROKEAHA.121.034222","journal-title":"Stroke"},{"key":"10067_CR5","doi-asserted-by":"publisher","unstructured":"Smith EE, Saver JL, Alexander DN, et al; AHA\/ASA Stroke Performance Oversight Committee. Clinical performance measures for adults hospitalized with acute ischemic stroke: performance measures for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014 Nov;45(11):3472\u201398. https:\/\/doi.org\/10.1161\/STR.0000000000000045. Epub 2014 Sep 25. PMID: 25256184.","DOI":"10.1161\/STR.0000000000000045"},{"key":"10067_CR6","doi-asserted-by":"publisher","unstructured":"Fonarow GC, Smith EE, Saver JL, et al. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association\/American Stroke Association\u2019s Target: Stroke initiative. Stroke. 2011;42:2983\u20132989. [PMID: 21885841] https:\/\/doi.org\/10.1161\/STROKEAHA.111.621342","DOI":"10.1161\/STROKEAHA.111.621342"},{"key":"10067_CR7","doi-asserted-by":"publisher","unstructured":"Zhu J, Kamel H, Gupta A, et al. Prioritizing Quality Measures in Acute Stroke Care : A Cost-Effectiveness Analysis. Ann Intern Med. 2023 May;176(5):649\u2013657. https:\/\/doi.org\/10.7326\/M22-3186. Epub 2023 May 2. PMID: 37126821; PMCID: PMC10211083.","DOI":"10.7326\/M22-3186"},{"key":"10067_CR8","doi-asserted-by":"crossref","unstructured":"American Diabetes Association, Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45(Suppl. 1)","DOI":"10.2337\/dc22-Sint"},{"key":"10067_CR9","doi-asserted-by":"crossref","unstructured":"Meschia JF, Bushnell C, Boden-Albala B, et al; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Functional Genomics and Translational Biology, and Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 2014;45:3754\u20133832.","DOI":"10.1161\/STR.0000000000000046"},{"key":"10067_CR10","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.2337\/dc10-0843","volume":"33","author":"R Li","year":"2010","unstructured":"Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010;33:1872-1894.","journal-title":"Diabetes Care"},{"issue":"11","key":"10067_CR11","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-e646. https:\/\/doi.org\/10.1161\/CIR.0000000000000678.","journal-title":"Circulation"},{"key":"10067_CR12","doi-asserted-by":"publisher","unstructured":"Kuo S, Yang CT, Herman WH, Lisabeth LD, Ye W. National Trends in the Achievement of Recommended Strategies for Stroke Prevention in U.S. Adults With Type 2 Diabetes, 2001\u20132018. Diabetes Care. 2022 Sep 1;45(9):2003\u20132011. https:\/\/doi.org\/10.2337\/dc21-2283. PMID: 35834174; PMCID: PMC9472506.","DOI":"10.2337\/dc21-2283"},{"key":"10067_CR13","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https:\/\/diabetesresearch.org\/diabetes-statistics\/. (Last accessed 09\/17\/2024)"},{"issue":"1","key":"10067_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2337\/ds19-0029.PMID:32116448;PMCID:PMC7026754","volume":"33","author":"SL Karam","year":"2020","unstructured":"Karam SL, Dendy J, Polu S, Blonde L. Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences. Diabetes Spectr. 2020 Feb;33(1):8-15. https:\/\/doi.org\/10.2337\/ds19-0029. PMID: 32116448; PMCID: PMC7026754.","journal-title":"Diabetes Spectr"},{"key":"10067_CR15","doi-asserted-by":"publisher","unstructured":"Emily D. Parker, Janice Lin, et al. Economic Costs of Diabetes in the U.S. in 2022. Diabetes Care 2 January 2024; 47 (1): 26\u201343. https:\/\/doi.org\/10.2337\/dci23-0085","DOI":"10.2337\/dci23-0085"},{"key":"10067_CR16","doi-asserted-by":"publisher","unstructured":"Rumbold B, Baker R, Ferraz O, et al. Universal health coverage, priority setting, and the human right to health. Lancet. 2017 Aug 12;390(10095):712\u2013714. https:\/\/doi.org\/10.1016\/S0140-6736(17)30931-5. Epub 2017 Apr 26. PMID: 28456508; PMCID: PMC6728156.","DOI":"10.1016\/S0140-6736(17)30931-5"},{"key":"10067_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703\u201313.","journal-title":"BMJ"},{"key":"10067_CR18","doi-asserted-by":"crossref","unstructured":"Lindholm LH, Ibsen H, Dahlof B, et al, for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004\u201310.","DOI":"10.1016\/S1062-1458(02)00776-6"},{"key":"10067_CR19","doi-asserted-by":"crossref","unstructured":"Patel A, ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829\u201340.","DOI":"10.1016\/S0140-6736(07)61303-8"},{"key":"10067_CR20","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575\u201385.","journal-title":"N Engl J Med"},{"key":"10067_CR21","doi-asserted-by":"publisher","unstructured":"Ananthapavan J, Sacks G, Brown V, et al. Carter R. Priority-setting for obesity prevention-The Assessing Cost-Effectiveness of obesity prevention policies in Australia (ACE-Obesity Policy) study. PLoS One. 2020 Jun 19;15(6):e0234804. https:\/\/doi.org\/10.1371\/journal.pone.0234804. PMID: 32559212; PMCID: PMC7304600.","DOI":"10.1371\/journal.pone.0234804"},{"issue":"6","key":"10067_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1586\/14737167.8.6.593","volume":"8","author":"R Carter","year":"2008","unstructured":"Carter R, Vos T, Moodie M, Haby M, Magnus A, Mihalopoulos C. Priority setting in health: origins, description and application of the Australian Assessing Cost-Effectiveness initiative. Expert Rev Pharmacoecon Outcomes Res. 2008 Dec;8(6):593-617. https:\/\/doi.org\/10.1586\/14737167.8.6.593. PMID: 20528370.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10067_CR23","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.2337\/diacare.28.12.2856","volume":"28","author":"H Zhou","year":"2005","unstructured":"Zhou H, Isaman DJM, Messinger S, et al. A Computer Simulation Model of Diabetes Progression, Quality of Life, and Cost. Diabetes Care 28:2856-2863, 2005.","journal-title":"Diabetes Care"},{"key":"10067_CR24","doi-asserted-by":"crossref","unstructured":"Ye W, Brandle M, Brown MB, Herman WH, The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation, Diabetes Technology and Therapeutics, Volume 17, Number 11, 2015","DOI":"10.1089\/dia.2014.0304"},{"key":"10067_CR25","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.2337\/diacare.26.8.2300","volume":"26","author":"M Brandle","year":"2003","unstructured":"Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003; 26:2300-4.","journal-title":"Diabetes Care"},{"key":"10067_CR26","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.2337\/diacare.25.12.2238","volume":"25","author":"JT Coffey","year":"2002","unstructured":"Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 25:2238\u20132243, 2002","journal-title":"Diabetes Care"},{"key":"10067_CR27","unstructured":"https:\/\/michigandiabetesmodelinggroup.github.io\/Software_App\/MMD_3_2 (Last assessed on Aug 18, 2025)"},{"issue":"2","key":"10067_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263-72.","journal-title":"Chest"},{"key":"10067_CR29","doi-asserted-by":"crossref","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140\u2013149.","DOI":"10.2337\/dc14-2441"},{"key":"10067_CR30","doi-asserted-by":"publisher","first-page":"554","DOI":"10.7326\/0003-4819-154-8-201104190-00007","volume":"154","author":"F Ismail-Beigi","year":"2011","unstructured":"Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554-559.","journal-title":"Ann Intern Med"},{"key":"10067_CR31","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Cardiovascular disease and risk management. Sec. 10. In Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45(Suppl. 1):S144-S174.","DOI":"10.2337\/dc22-S010"},{"key":"10067_CR32","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care, and immunization. Sec. 5. In Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45(Suppl. 1):S60-S82.","DOI":"10.2337\/dc22-S005"},{"issue":"1","key":"10067_CR33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52102.PMID:38344627;PMCID:PMC10858725","volume":"16","author":"CN Onwuzo","year":"2024","unstructured":"Onwuzo CN, Olukorode J, Sange W, et al. A Review of Smoking Cessation Interventions: Efficacy, Strategies for Implementation, and Future Directions. Cureus. 2024 Jan 11;16(1):e52102. https:\/\/doi.org\/10.7759\/cureus.52102. PMID: 38344627; PMCID: PMC10858725.","journal-title":"Cureus"},{"issue":"1","key":"10067_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/M20-1392","volume":"174","author":"DJ Vanness","year":"2021","unstructured":"Vanness DJ, Lomas J, Ahn H. A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States. Ann Intern Med. 2021 Jan;174(1):25-32. https:\/\/doi.org\/10.7326\/M20-1392. Epub 2020 Nov 3. PMID: 33136426.","journal-title":"Ann Intern Med"},{"issue":"15","key":"10067_CR35","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jama.2023.1792","volume":"329","author":"PJ Neumann","year":"2023","unstructured":"Neumann PJ,\u00a0Kim DD. Cost-effectiveness Thresholds Used by Study Authors, 1990-2021.\u00a0JAMA.\u00a02023;329(15):1312\u20131314. https:\/\/doi.org\/10.1001\/jama.2023.1792","journal-title":"JAMA"},{"issue":"16","key":"10067_CR36","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1001\/jama.2022.11688","volume":"329","author":"M Suran","year":"2023","unstructured":"Suran M. All 3 Major Insulin Manufacturers Are Cutting Their Prices-Here\u2019s What the News Means for Patients With Diabetes. JAMA. 2023 Apr 25;329(16):1337-1339. https:\/\/doi.org\/10.1001\/jama.2022.11688. PMID: 36988974.","journal-title":"JAMA"},{"issue":"10","key":"10067_CR37","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093\u20131103.","journal-title":"JAMA"},{"issue":"1","key":"10067_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health 2022;25(1):3\u20139.","journal-title":"Value Health"},{"issue":"7","key":"10067_CR39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamaneurol.2015.0284","volume":"72","author":"AP Saltman","year":"2015","unstructured":"Saltman AP, Silver FL, Fang J, Stamplecoski M, Kapral MK. Care and Outcomes of Patients With In-Hospital Stroke. JAMA Neurol. 2015 Jul;72(7):749-55. https:\/\/doi.org\/10.1001\/jamaneurol.2015.0284. PMID: 25938195.","journal-title":"JAMA Neurol"},{"key":"10067_CR40","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","volume":"52","author":"DO Kleindorfer","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association. Stroke 2021;52:e364-e467.","journal-title":"Stroke"},{"issue":"7","key":"10067_CR41","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1007\/s00125-021-05436-0","volume":"64","author":"M Benn","year":"2021","unstructured":"Benn M, Emanuelsson F, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis. Diabetologia. 2021 Jul;64(7):1492-1503. https:\/\/doi.org\/10.1007\/s00125-021-05436-0. Epub 2021 Mar 25. PMID: 33765180","journal-title":"Diabetologia"},{"issue":"4","key":"10067_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41574-022-00793-1","volume":"19","author":"AYY Cheng","year":"2023","unstructured":"Cheng AYY, Gomes MB, Kalra S, Kengne AP, Mathieu C, Shaw JE. Applying the WHO global targets for diabetes mellitus. Nat Rev Endocrinol. 2023 Apr;19(4):194-200. https:\/\/doi.org\/10.1038\/s41574-022-00793-1. Epub 2023 Jan 16. PMID: 36646874.","journal-title":"Nat Rev Endocrinol."},{"key":"10067_CR43","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1161\/HYPERTENSIONAHA.118.11558","volume":"72","author":"BM Egan","year":"2018","unstructured":"Egan BM, Sutherland S, Rakotz M, Yang J, Hanlin RB, Davis R, Wozniak G. Improving hypertension control in primary care with the Measure accurately, Act rapidly and Partner with patients (MAP) Protocol: results at 6 and 12 months. Hypertension. 2018;72:1320\u20131327.","journal-title":"Hypertension."},{"key":"10067_CR44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/jama.2013.108769","volume":"310","author":"MG Jaffe","year":"2013","unstructured":"Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310:699\u2013705. https:\/\/doi.org\/10.1001\/jama.2013.108769","journal-title":"JAMA."},{"key":"10067_CR45","doi-asserted-by":"publisher","unstructured":"Konnyu KJ, Yogasingam S, L\u00e9pine J, Sullivan K, Alabousi M, Edwards A, Hillmer M, Karunananthan S, Lavis JN, Linklater S, Manns BJ, Moher D, Mortazhejri S, Nazarali S, Paprica PA, Ramsay T, Ryan PM, Sargious P, Shojania KG, Straus SE, Tonelli M, Tricco A, Vachon B, Yu CH, Zahradnik M, Trikalinos TA, Grimshaw JM, Ivers N. Quality improvement strategies for diabetes care:\u00a0Effects on outcomes for adults living with diabetes. Cochrane Database Syst Rev. 2023 May 31;5(5):CD014513. https:\/\/doi.org\/10.1002\/14651858.CD014513. PMID: 37254718; PMCID: PMC10233616.","DOI":"10.1002\/14651858.CD014513"},{"key":"10067_CR46","doi-asserted-by":"publisher","unstructured":"Gomes MB, Rathmann W, Charbonnel B, Khunti K, Kosiborod M, Nicolucci A, Pocock SJ, Shestakova MV, Shimomura I, Tang F, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Ji L; DISCOVER investigators. Treatment of type 2 diabetes mellitus worldwide: baseline patient characteristics in the global DISCOVER study. Diabetes Res Clin Pract. 2019 May;151:20\u201332. https:\/\/doi.org\/10.1016\/j.diabres.2019.03.024. Epub 2019 Mar 20. PMID: 30904743","DOI":"10.1016\/j.diabres.2019.03.024"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10067-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-10067-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10067-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:51:08Z","timestamp":1778770268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-10067-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10067"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-10067-x","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All analyses involved secondary analyses of publicly available, de-identified data. A request for exemption from Human Subjects approval was submitted to the University of Michigan Institutional Research Board and was approved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"No disclosures were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}